Characterization of mouse models of synucleinopathies
Our findings highlight limitations in both the M83 and WT αSyn PFF models. Given these results, we will focus on humanized WT, A53T, and E83Q SNCA models, which are expected to provide more physiologically relevant αSyn expression and improved reliability for studying synucleinopathies. These models may enhance our understanding of disease progression and facilitate the identification of potential therapeutic targets.
Authors
- Joel C. Watts (ORCID: https://orcid.org/0000-0002-2604-2925)
- Ravi S. Menon (ORCID: https://orcid.org/0000-0002-7916-0263)
- Thomas M. Durcan (ORCID: https://orcid.org/0000-0003-3942-1956)
- Vânia F. Prado (ORCID: https://orcid.org/0000-0003-4994-6393)
- Czarina Evangelista (ORCID: https://orcid.org/0000-0002-7745-5252)
- Timothy J. Bussey (ORCID: https://orcid.org/0000-0002-3180-3709)
- Edward A. Fon
- Lisa M Saksida
- Latiyah TC Timothy
- Vladislav Novikov
- Marco AM Prado
- Kellly Summers
Institutions
- Western University (CA)
- Montreal Neurological Institute and Hospital (CA)
- University of Toronto (CA)
- Robarts Clinical Trials (CA)
- McGill University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_106153
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00